ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
Phase 3
Completed
- Conditions
- Lupus Nephritis
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2007-01-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT00429377
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
Phase 4
Withdrawn
- Conditions
- Aspergillosis/BloodAspergillosis/Invasive
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00423163
Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2010-04-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 39
- Registration Number
- NCT00418873
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Phase 3
Completed
- Conditions
- AspergillosisInvasive Fungal Infection
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 527
- Registration Number
- NCT00412893
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Ciudad Autonoma, Argentina
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Chicago, Division of Infectious Diseases, Chicago, Illinois, United States
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Phase 3
Completed
- Conditions
- MycosesCandidiasis, InvasiveCandidemia
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00413218
- Locations
- 🇺🇸
Idaho Falls Infectious Diseases PLLC, Idaho Falls, Idaho, United States
🇺🇸Somero Research Corporation, Palm Desert, California, United States
🇺🇸Loyola University Hospital, Maywood, Illinois, United States
Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: ASK8007Drug: Placebo
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 54
- Registration Number
- NCT00411424
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Phase 2
Completed
- Conditions
- Lower Urinary Tract SymptomsBladder Outlet Obstruction
- Interventions
- Drug: PlaceboDrug: Mirabegron
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00410514
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 367
- Registration Number
- NCT00408239
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
Phase 4
Completed
- Conditions
- HypercholesteremiaCoronary Artery Disease
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00408382
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 112
- Registration Number
- NCT00384202
© Copyright 2025. All Rights Reserved by MedPath